ESR1 and breast carcinoma: TNBC has been characterized as exhibiting a negative profile for the three markers used in the molecular classification of breast cancer, ER-/progesterone receptor negative (PR-)/human epidermal growth factor receptor 2 negative (HER2-) [7, 9, 10].